Drugs / HMI-115
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05324293 | May 2022 → Sep 2023 | androgenetic alopecia | Hope Medicine (Nanjing) Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05101317 | Oct 2021 → Sep 2024 | endometriosis | Hope Medicine (Nanjing) Co., Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07318688 | Mar 2026 → Mar 2028 expected | endometriosis | Hope Medicine (Nanjing) Co., Ltd | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06118866 Comparator | Sep 2023 → Aug 2024 | androgenetic alopecia | Hope Medicine (Nanjing) Co., Ltd | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-26 | BioInvent International AB | BioInvent achieves Phase 3 milestone for HMI-115 in endometriosis bioinvent.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HMI-115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05324293 ↗ |
| Modality | Monoclonal antibody | “HMI-115 is human monoclonal antibody” NCT05101317 ↗ |
| Route | Subcutaneous | “subcutaneously injection” NCT05101317 ↗ |